CN1450913A - 二膦酸酯、雌激素药物以及任选雌激素的联合应用 - Google Patents
二膦酸酯、雌激素药物以及任选雌激素的联合应用 Download PDFInfo
- Publication number
- CN1450913A CN1450913A CN01815091A CN01815091A CN1450913A CN 1450913 A CN1450913 A CN 1450913A CN 01815091 A CN01815091 A CN 01815091A CN 01815091 A CN01815091 A CN 01815091A CN 1450913 A CN1450913 A CN 1450913A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- phenyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21606900P | 2000-07-06 | 2000-07-06 | |
| US21618800P | 2000-07-06 | 2000-07-06 | |
| US60/216,069 | 2000-07-06 | ||
| US60/216,188 | 2000-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1450913A true CN1450913A (zh) | 2003-10-22 |
Family
ID=26910620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01815091A Pending CN1450913A (zh) | 2000-07-06 | 2001-06-29 | 二膦酸酯、雌激素药物以及任选雌激素的联合应用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1299093A2 (fr) |
| JP (1) | JP2004502730A (fr) |
| CN (1) | CN1450913A (fr) |
| AU (1) | AU2001273125A1 (fr) |
| BR (1) | BR0112364A (fr) |
| CA (1) | CA2415052A1 (fr) |
| MX (1) | MXPA02012897A (fr) |
| WO (1) | WO2002003976A2 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002003989A2 (fr) * | 2000-07-06 | 2002-01-17 | Wyeth | Therapie permettant d'inhiber l'incontinence du sphincter |
| US6376486B1 (en) | 2000-07-06 | 2002-04-23 | American Home Products Corporation | Methods of inhibiting sphincter incontinence |
| US6455568B2 (en) | 2000-07-06 | 2002-09-24 | Wyeth | Combination therapy for inhibiting sphincter incontinence |
| CN1681386B (zh) | 2002-07-24 | 2010-05-26 | 儿童医院医疗中心 | 含有对映体牛尿酚的组合物和产物及其制备方法 |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| US20060122262A1 (en) | 2002-10-29 | 2006-06-08 | Lephart Edwin D | Use of equol for treating androgen mediated diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| RU2315603C2 (ru) † | 2002-12-20 | 2008-01-27 | Ф.Хоффманн-Ля Рош Аг | Композиция с высокой дозой ибандроната |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| KR20240142622A (ko) | 2015-10-01 | 2024-09-30 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| PT3386500T (pt) | 2015-12-09 | 2023-01-06 | Univ Illinois | Supressores seletivos do recetor de estrogénio à base de benzotiofeno |
| EP3454856B1 (fr) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN120887906A (zh) | 2016-05-10 | 2025-11-04 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| JP2019520379A (ja) | 2016-07-01 | 2019-07-18 | ジー１ セラピューティクス， インコーポレイテッド | ピリミジン系の抗増殖剤 |
| WO2018081168A2 (fr) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène |
| CA3048057A1 (fr) | 2017-01-06 | 2018-07-12 | G1 Therapeutics, Inc. | Polytherapie pour le traitement du cancer |
| AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| WO2018237026A1 (fr) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | Dégrons et dégronimères à liaison n/o pour la dégradation de protéines |
| ES2988261T3 (es) | 2017-06-29 | 2024-11-19 | G1 Therapeutics Inc | Formas mórficas de GIT38 y métodos de fabricación de las mismas |
| WO2020132561A1 (fr) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Dégradation ciblée de protéines |
| AU2020311337B2 (en) | 2019-07-07 | 2026-02-26 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| PH12022550950A1 (en) | 2019-12-20 | 2023-07-03 | C4 Therapeutics Inc | Isoindolinone and indazole compounds for the degradation of egfr |
| JP7746278B2 (ja) | 2020-03-05 | 2025-09-30 | シーフォー セラピューティクス， インコーポレイテッド | Ｂｒｄ９の標的分解のための化合物 |
| JP2023538517A (ja) | 2020-08-05 | 2023-09-08 | シーフォー セラピューティクス， インコーポレイテッド | Ｒｅｔの標的分解のための化合物 |
| EP4351583A4 (fr) | 2021-06-08 | 2025-06-04 | C4 Therapeutics, Inc. | Agents thérapeutiques pour la dégradation de braf mutante |
| CN119998285A (zh) | 2022-08-03 | 2025-05-13 | 百时美施贵宝公司 | 用于调控ret蛋白的化合物 |
| CN120530116A (zh) | 2022-11-04 | 2025-08-22 | 百时美施贵宝公司 | Ret-ldd蛋白抑制剂 |
| KR20250117789A (ko) | 2022-11-04 | 2025-08-05 | 브리스톨-마이어스 스큅 컴퍼니 | Ret-ldd 단백질 분해제 |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU760378B2 (en) * | 1998-05-15 | 2003-05-15 | Wyeth Llc | 2-phenyl-1-(4-(2-aminoethoxy)-benzyl)-indole in combination with estrogens |
| WO1999059969A1 (fr) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | Compositions comprenant des composes a base de 2-phenyl-indole et de formulations d'oestrogenes |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
-
2001
- 2001-06-29 CA CA002415052A patent/CA2415052A1/fr not_active Abandoned
- 2001-06-29 CN CN01815091A patent/CN1450913A/zh active Pending
- 2001-06-29 WO PCT/US2001/020970 patent/WO2002003976A2/fr not_active Ceased
- 2001-06-29 MX MXPA02012897A patent/MXPA02012897A/es unknown
- 2001-06-29 JP JP2002508431A patent/JP2004502730A/ja active Pending
- 2001-06-29 EP EP01952365A patent/EP1299093A2/fr not_active Withdrawn
- 2001-06-29 AU AU2001273125A patent/AU2001273125A1/en not_active Abandoned
- 2001-06-29 BR BR0112364-5A patent/BR0112364A/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004502730A (ja) | 2004-01-29 |
| WO2002003976A3 (fr) | 2003-01-03 |
| MXPA02012897A (es) | 2003-10-24 |
| EP1299093A2 (fr) | 2003-04-09 |
| WO2002003976A2 (fr) | 2002-01-17 |
| AU2001273125A1 (en) | 2002-01-21 |
| CA2415052A1 (fr) | 2002-01-17 |
| BR0112364A (pt) | 2003-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1450913A (zh) | 二膦酸酯、雌激素药物以及任选雌激素的联合应用 | |
| US6358991B2 (en) | Methods of treating neuropeptide Y-related conditions | |
| CN1468110A (zh) | 他汀类、雌激素药物以及任选雌激素的联合应用 | |
| CN101416949A (zh) | 雌激素药物药用组合物 | |
| WO2002003992A2 (fr) | Therapie pour degenerescence osseuse en rapport avec une prothese | |
| US6509332B2 (en) | Methods of treating excessive intraocular pressure | |
| US20020016318A1 (en) | Methods of treating breast disorders | |
| US20020028805A1 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
| WO2002003975A2 (fr) | Combinaisons d'inhibiteurs specifiques de recaptage de la serotonine et d'agents oestrogeniques | |
| AU2001271741A1 (en) | Pharmaceutical compositions of estrogenic agents | |
| WO2002003989A2 (fr) | Therapie permettant d'inhiber l'incontinence du sphincter | |
| US6455568B2 (en) | Combination therapy for inhibiting sphincter incontinence | |
| US6369051B1 (en) | Combinations of SSRI and estrogenic agents | |
| US20020028792A1 (en) | Combinations of bisphosphonates, estrogens and estrogenic agents | |
| US6635660B2 (en) | Methods of inhibiting sphincter incontinence | |
| US20020019373A1 (en) | Combinations of bisphosphonates and estrogenic agents | |
| US20020025952A1 (en) | Combinations of statins, estrogens and estrogenic agents | |
| US20020028800A1 (en) | Combination therapy for prosthesis-related bone degeneration | |
| US6465454B2 (en) | Combinations of statins and estrogenic agents | |
| EP1656938A1 (fr) | Combinaisons d'inhibiteurs spécifiques du recaptage de la sérotonine avec des agents oestrogéniques | |
| US20020022613A1 (en) | Methods of treating prosthesis-related bone degeneration | |
| HK1059897A (en) | Pharmaceutical compositions of estrogenic agents | |
| HK1089695A (en) | Combinations of ssri and estrogenic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |